Full-Time

Director – IT

Posted on 6/4/2025

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Expert

Chennai, Tamil Nadu, India

Category
Full-Stack Engineering
Software Engineering
Required Skills
Product Management
Data Analysis
Requirements
  • 10+ years' experience in progressive IT as part of solution delivery with an emphasis on leadership and planning (or other applicable areas)
  • Subject Matter Expertise in Product Management
  • Proven track record of success in leadership role in order to achieve goals leading to continued success
  • Proven ability to attract, retain, and develop talented direct reports
  • Energetic individual, eager to manage multiple activities and priorities
  • Dedication to quality in all work tasks and deliverables
  • Ability to excite and motivate employees, partner and customers with a compelling vision
  • Excellent understanding of the software business and its practices
  • Active involvement in the use of online communities and an understanding of the use of current online and digital technologies
  • Ability to travel (approximately 30-40%) domestic and/or international
Responsibilities
  • Leading and coordinating the delivery of software solutions and personnel throughout the product development lifecycle
  • Managing interactions and expectations with the group’s stakeholders – both internal and external to ICON
  • Providing strategic oversight and enabling pipelines for the delivery of new applications and enhancements
  • Ensuring appropriate alignment and transparency across teams
  • Release planning, staffing, budget forecasting, resolving issues and mitigating risks
  • Planning and driving the roadmap for delivery of new products and capabilities based on strategy, vision, and priorities set by stakeholders
  • Developing and leading a multi-location product management/business analyst unit
  • Working with Engineering, Testers, Validators and Architecture, QA, PMO, Operations resources to ensure the delivery of innovative solutions
  • Ownership of respective operational and CAPEX budget
  • Developing and executing product management plans and managing schedules and resource allocation and budget
  • Building, developing and retaining high performing teams
  • Ensuring practices and operations to ensure reproducible ways of working and high quality
  • Engaging in hands-on, in-depth analysis, review and design of the inputs to software design

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, ensuring that they can meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the quality of life for patients.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances trial participant management and engagement.
  • Increased AI use in biomarker detection boosts ICON's neurodegenerative research capabilities.
  • Barry Balfe's appointment as COO strengthens ICON's operational excellence and growth potential.

What critics are saying

  • Securities fraud lawsuit poses financial and reputational risks for ICON.
  • Complexity in multi-indication trials may lead to inefficiencies in clinical development.
  • Underutilization of biomarkers in trials could hinder ICON's research efficiency.

What makes Icon unique

  • ICON's global network spans 53 countries, offering comprehensive clinical research services.
  • Focus on reducing time to market, cost, and increasing quality sets ICON apart.
  • ICON's expertise in multi-indication studies enhances its competitive edge in clinical trials.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

BioSpace
May 7th, 2025
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.

PharmiWeb
May 7th, 2025
Global Icon Survey Shows Need For More Efficient Obesity Clinical Trial Design To Realise Full Potential Of Next-Gen Multi-Indication Therapies

Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

INACTIVE